BSEM (BioStem Technologies Inc.) stock: $1.13, $21.1M market cap, $7.0M cash, $14.1M EV, $32.7M fully diluted market cap. Lead program: BR-AC (Non-infected Venous Leg Ulcer). Data from Fully Diluted's biotech stocks database.
What they do
BioStem Technologies is a regenerative medicine company focused on harnessing the natural properties of perinatal tissue for the development, manufacture, and sale of allografts for use in wound care, with its lead products placental tissue-derived allografts in development for diabetic foot ulcers.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Non-infected Venous Leg Ulcer; Venous Leg Ulcer; Venous Insufficiency
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.